Indivior Reports Second Quarter 2025 Financial Results and Raises FY 2025 Financial Guidance

Core Insights - Indivior PLC reported strong financial results for Q2 2025, driven by net revenue growth from SUBLOCADE and pricing stability in SUBOXONE Film, prompting an increase in financial guidance for the year [2][4][6] Financial Performance - Total net revenue for Q2 2025 was $302 million, a 1% increase from $299 million in Q2 2024 [8][20] - SUBLOCADE net revenue reached $209 million, up 9% year-over-year and 19% compared to Q1 2025 [6][8] - U.S. SUBLOCADE net revenue was $195 million, reflecting a 9% increase from Q2 2024 and a 20% increase from Q1 2025 [7][8] - Non-GAAP gross margin for Q2 was 84%, unchanged from Q2 2024 [16] Revised Financial Guidance - The company raised its 2025 financial guidance, with total net revenue now expected to be between $1,030 million and $1,080 million, up from the previous range of $955 million to $1,025 million [4][6] - Adjusted EBITDA guidance was increased to a range of $275 million to $300 million, up from $220 million to $260 million [4][6] Strategic Initiatives - The Indivior Action Agenda is being implemented to enhance operational momentum, focusing on U.S. SUBLOCADE growth and organizational simplification [2][6] - The company has strengthened its executive team and board with new appointments to support its strategic goals [7] Market Position and Developments - Indivior has been included in the Russell 2000® Index and Russell 3000® Index, enhancing its market visibility [7] - New data presented at scientific meetings indicate that higher doses of SUBLOCADE may improve outcomes for patients with high fentanyl use [7]